New pill shows promise against lung cancer brain metastases
Disease control
Completed
This study tested a new drug called AZD3759 against standard targeted therapies (erlotinib or gefitinib) in 492 people with advanced EGFR-mutant lung cancer that had spread to the brain. The goal was to see if AZD3759, which is designed to better reach the brain, could keep the c…
Phase: PHASE2, PHASE3 • Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 16:13 UTC